Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.

ABSTRACT: Therapeutic strategies to deplete lymphocytes, especially regulatory T cells, in cancer patients have been proposed to increase the benefits of (immuno)chemotherapy. In this study, we explored the influence of temozolomide (TMZ) on different T-cell populations and addressed if the depletion of CD4⁺ T cells would be associated to the clinical benefits of TMZ. Patients were treated with TMZ (150 mg/m² daily, every two weeks on a four-week schedule) until disease progression. Changes in T-lymphocyte subsets were characterized by flow cytometry. All patients enrolled in this study had histologically verified unresectable stage IV melanoma. Objective responses were induced in 12.5% of the patients, while 42.5% of them obtained short-term disease stabilization. The median p

SUBMITTER: Iversen TZ 

PROVIDER: S-EPMC3601183 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature